Skip to main content

Table 2 Selected data of copanlisib monotherapy in relapsed or refractory B-cell-lymphoma subtypes in clinical trials

From: A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

Trial Subtype of lymphoma (%) Number of patients OR (%) CR (%) summary of treatment-emergent ≥ grade 3 (%) occurring in ≥10% of the total population
Phase I [18] FL (66.6), DLBCL (33.3) 9 78% 11% hyperglycemia (33), hypertension (33),
lung infection (22),
neutropenia (11),
rash (11),
anemia (11)
Phase II [20] DLBCL (100) 79 19.4 5 hyperglycemia (33), hypertension (31)
Phase II [21] FL (73),
MZL (16),
SLL 8 (6),
LPL/WM (4),
DLBCL (1)
142 59 (overall cohort),
70 (only MZL)
12 (overall cohort),
9 (only MZL)
hyperglycemia (41), hypertension (24),
lung infection (15),
neutropenia (24)
  1. FL follicular lymphoma, DLBCL diffuse large B-cell lymphoma, MZL marginal zone lymphoma, SLL small lymphocytic lymphoma, LPL lymphoplasmacytic lymphoma, WM Waldenström’s macroglobulinemia, OR overall response, CR complete response